These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 6226084)

  • 21. Fibrinogen and fibrin degradation products: their differentiation.
    Edgington TS
    Thromb Diath Haemorrh; 1975 Dec; 34(3):671-6. PubMed ID: 54944
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of crosslinking on the structure of solubilized fibrin degradation products in whole plasma.
    Carroll RC; Lockhart MS; Taylor FB
    J Lab Clin Med; 1984 May; 103(5):695-703. PubMed ID: 6232329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Methods of determination of fibrin fibrinogen degradation products (review of the literature)].
    Guseínov ChS; Prozorovskaia NN; Mikhaĭlova ND; Gorelova AM; Lagutina NIa
    Lab Delo; 1978; (5):259-66. PubMed ID: 79007
    [No Abstract]   [Full Text] [Related]  

  • 24. GPR-phoresis, a novel approach to determining fibrin monomer and other macromolecular derivatives of fibrinogen and fibrin in blood.
    Shainoff JR; Urbanic DA; DiBello PM; Valenzuela V
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):87-92. PubMed ID: 8457658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparative study of immunological determination of fibrin and its degradation products. (2)].
    Yasuda J; Tabara C; Hidano M; Mizuno Y; Kazama M
    Rinsho Byori; 1974 Oct; 22(10 Suppl):110. PubMed ID: 4475720
    [No Abstract]   [Full Text] [Related]  

  • 26. [Diagnostic significance of proteolytic breakdown products of fibrinogen and fibrin].
    Heene DL; Genth K
    Internist (Berl); 1984 Feb; 25(2):93-101. PubMed ID: 6231262
    [No Abstract]   [Full Text] [Related]  

  • 27. [Antifibrinolytic effect of heparin].
    Rozenfel'd MA; Leonova VB; Khavkina LS; Meshkov BB
    Biokhimiia; 1984 Oct; 49(10):1672-8. PubMed ID: 6240283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Content of soluble fibrin monomeric complexes, factor XIII and fibrin(ogen) degradation products in neonatal asphyxia].
    Suzuki S; Graeff H; Hafter R
    Arch Gynecol; 1979 Jul; 228(1-4):626-7. PubMed ID: 485520
    [No Abstract]   [Full Text] [Related]  

  • 29. [Kinetics of fibrin lysis by plasmin: inhibition by fibrin degradation products].
    Zhitkova IuV; Aĭsina RB; Varfolomeev SD
    Bioorg Khim; 1996 Dec; 22(12):911-5. PubMed ID: 9054342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative study of various rapid methods of determining fibrinogen transformation products in the diagnosis of intravascular coagulation and fibrinolysis].
    Lychev VG; Momot AP; Cherkashin GV
    Ter Arkh; 1984; 56(6):106-9. PubMed ID: 6474366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The action of regulator peptides with different biological activities on the process of fibrin-monomer polymerization and on nonenzymatic fibrinolysis].
    Ashmarin IP; Liapina LA; Pastorova VE; Kudriashov BA
    Patol Fiziol Eksp Ter; 1991; (4):3-5. PubMed ID: 1798648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The role of D2-E2 centers of interdomain binding of fibrin monomer during fibrinogen co-polymerization with an NH2-terminal disulfide knot of fibrin].
    Pozdniakova TM; Rybachuk VN; Ugarova TP
    Biokhimiia; 1987 Apr; 52(4):592-8. PubMed ID: 3593791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [alphaC domains of fibrinogen molecules as the structures accelerating fibrin assembly].
    Medved' LV; Gorkun OV; Maniakov VF; Belitser VA
    Mol Biol (Mosk); 1986; 20(2):461-70. PubMed ID: 3702870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specific identification of fibrin polymers, fibrinogen degradation products, and crosslinked fibrin degradation products in plasma and serum with a new sensitive technique.
    Connaghan DG; Francis CW; Lane DA; Marder VJ
    Blood; 1985 Mar; 65(3):589-97. PubMed ID: 3971042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Alterations in fibrinolytic activity in 94 cases of oral surgery. Influence of stress (author's transl)].
    Saulnier J; Conard J; Horellou MH; Schuhmann C; Samama M
    Ann Chir; 1980 Apr; 34(4):290-6. PubMed ID: 6446255
    [No Abstract]   [Full Text] [Related]  

  • 36. The structure of soluble fibrin complexes and fibrin degradation products after Echis carinatus bite.
    Edgar W; Warrell MJ; Warrell DA; Prentice CR
    Br J Haematol; 1980 Mar; 44(3):471-81. PubMed ID: 7378311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immunoelectrophoretic study of fibrinogen and of degradation products of fibrinogen and fibrin].
    Karpinskaia VM
    Probl Gematol Pereliv Krovi; 1968 Jan; 13(1):53-6. PubMed ID: 5736826
    [No Abstract]   [Full Text] [Related]  

  • 38. Fibrin degradation products. A review of structures found in vitro and in vivo.
    Gaffney PJ
    Ann N Y Acad Sci; 2001; 936():594-610. PubMed ID: 11460518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble fibrin as a molecular marker for a pre-thrombotic state: a mini-review.
    Nieuwenhuizen W
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):93-6. PubMed ID: 8457659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Fibrinogen degradation products, soluble fibrin and antithrombin III in toxic goiter patients].
    Panchenko VM; Salakhidinov Z; Khaĭkina MB
    Probl Endokrinol (Mosk); 1979; 25(1):11-5. PubMed ID: 581702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.